Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome

Completed · Not applicable · Has a placebo group

Conditions studied: Dry Eye Syndrome

In brief

The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline, Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with lissamine green, and fluorescein tear break-up time) when compared to administration of placebo.

Key facts

Study ID
NCT01107964
Run by
Milton S. Hershey Medical Center
People needed
27
Starts
2010-07-01
Expected to finish
2015-06-15
Last updated by the study team
2017-12-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.